- |||||||||| TNX-1500 / Tonix, Massachusetts General Hospital
Experience with a Novel Delayed Immune Tolerance Protocol in Nonhuman Primates Based on aCD154, aCD2 and aCD28 (201-204_Level 2_South; In Person Only) - Aug 9, 2024 - Abstract #ACSCLINCON2024ACS_CLINCON_1076;
Induction treatment for donor bone marrow transplantation (BMT) was administered after a 4-month delay period under TNX-1500; BMT induction was comprised of one (Group 1) or two (Group 2) doses of total body irradiation, thymic irradiation, and horse anti-thymocyte globulin (ATG) followed by two (Group 1) or five (Group 2) weekly doses of ?CD2 and five weekly treatments with ?CD28 and TNX-1500... Although the combination of ?CD2 with ?CD28 promotes lymphocyte chimerism in this delayed BMT model, the high incidence of PTLD and opportunistic infection with CMV reflects overly intense immunosuppression and prevented assessment of the regimen
- |||||||||| TNX-1500 / Tonix, Massachusetts General Hospital, FR104 / OSE Immunotherapeutics, Asahi Kasei, Antova (ruplizumab) / Biogen
Combined Blockade of the CD154 and CD28 Co-Stimulation Pathways Attenuates Pathogenic Alloimmunity and Prolongs Survival in Cynomolgus Cardiac Allografts (109-AB, Level 1) - May 6, 2024 - Abstract #ATC2024ATC_2451;
*Purpose: TNX-1500 (TNX) is a novel humanized ?CD154 mAb that contains the hu5c8 Fab region and an IgG4 Fc region engineered to modulate Fc?R2 binding to reduce the risk of thromboembolic events seen with ruplizumab (hu5c8 IgG1) in previous clinical trials... Combined blockade of the CD154 and CD28 co-stimulation pathways is associated with durable protection from pathogenic alloimmunity in this stringent model, suggesting a promising approach for clinical translation.
- |||||||||| TNX-1500 / Tonix, Massachusetts General Hospital, Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Experience with a Novel Delayed Immune Tolerance Protocol in Nonhuman Primates Based on Anti-CD154, Anti-CD2, and Anti-CD28 (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_1377;
Induction treatment for donor bone marrow transplantation (BMT) was administered after a 4-month delay period under TNX-1500 monotherapy; BMT induction was comprised of one (Group 1) or two (Group 2) doses of total body irradiation, thymic irradiation, and rabbit anti-thymocyte globulin (ATG) followed by two (Group 1) or four (Group 2) weekly doses of anti-CD2 and 4 weekly treatments with ?CD28 and TNX-1500.* One graft rejected during the delay period; two others exhibited moderate rejection with preserved function while five exhibited normal histology and function. Although the combination of intensified ?CD2 with ?CD28 promotes robust lymphocyte chimerism in this well-established delayed BMT model, the high incidence of PTLD and opportunistic infection with CMV reflects overly intense immunosuppression and prevented assessment of the regimen's effectiveness to promote alloimmune tolerance in this model.
|
